Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

VYNE Therapeutics (VYNE) Operating Expenses (2016 - 2025)

VYNE Therapeutics' Operating Expenses history spans 10 years, with the latest figure at $7.6 million for Q2 2025.

  • For Q2 2025, Operating Expenses fell 28.16% year-over-year to $7.6 million; the TTM value through Dec 2025 reached $29.9 million, down 32.34%, while the annual FY2025 figure was $30.3 million, 31.31% down from the prior year.
  • Operating Expenses reached $7.6 million in Q2 2025 per VYNE's latest filing, down from $9.4 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $13.2 million in Q3 2024 to a low of $6.0 million in Q1 2023.
  • Average Operating Expenses over 5 years is $9.2 million, with a median of $9.3 million recorded in 2021.
  • Peak YoY movement for Operating Expenses: tumbled 94.49% in 2021, then skyrocketed 108.13% in 2024.
  • A 5-year view of Operating Expenses shows it stood at $9.1 million in 2021, then decreased by 12.38% to $8.0 million in 2022, then fell by 13.54% to $6.9 million in 2023, then skyrocketed by 86.07% to $12.9 million in 2024, then tumbled by 40.79% to $7.6 million in 2025.
  • Per Business Quant, the three most recent readings for VYNE's Operating Expenses are $7.6 million (Q2 2025), $9.4 million (Q1 2025), and $12.9 million (Q4 2024).